[January 07, 2015] |
|
Genomic Vision Achieves Major Milestone with Delivery of New High-Throughput Genome Analyzer to Quest Diagnostics
Genomic Vision (FR0011799907 - GV), a molecular
diagnostics company specialized in the development of diagnostic tests
for genetic diseases and cancers based on molecular combing, today
announces the delivery of a major milestone of its strategic
collaboration with Quest Diagnostics, the world's leading provider of
diagnostic information services. Genomic Vision has delivered a
high-throughput genome analyzer now operational at the Quest Diagnostics
clinical laboratory in San Juan Capistrano, Calif. Under terms of the
collaboration, Quest Diagnostics has the right to use the instrument to
create an additional laboratory-developed test for the detection of
mutations in the BRCA gene, which can cause hereditary breast and
ovarian cancer, and other complex diseases. The test would potentially
supplement Quest's BRCAvantage suite of BRCA test services based on
next-generation sequencing.
Genomic Vision's molecular combing technology allows the fluorescent
barcoding of multiple genes involved in disease development giving each
target gene a specific Genetic Morse Code. The analyzer detects and
identiies signature data coming from the Genetic Morse Code. It
provides a multiplexed solution to detect genomic aberrations involved
in complex diseases such as cancer, muscular and neuronal development
disorders.
The new analyzer was developed to increase throughput of diagnostic
screening volume and reduce turnaround times, for faster results
reporting.
In addition to BRCA, the collaborative terms also give Quest Diagnostics
the option to use the platform to accelerate the development of
lab-developed tests for other hereditary cancers, such as Lynch syndrome
or hereditary nonpolyposis colorectal cancer, as well as spinal muscular
atrophy.
Genomic Vision and Quest Diagnostics entered into a multi-year exclusive
collaboration based on Genomic Vision's proprietary molecular combing
genome-analysis technology in 2010. In 2013, Quest Diagnostics
introduced the first lab-developed test, for FSHD, a debilitating
myopathy, based on Genomic Vision's technology in the United States.
"This new platform has the potential to enable us to develop new test
services for improving clinical decisions involving of the care of
patients at risk of developing several serious pathologies, such as
hereditary breast cancer," states Dr. Charles (Buck) Strom,
Medical Director of Quest Diagnostics Nichols Institute.
"We are very pleased to offer, on time, to our US partner the new
genome analyzer. This achievement was made possible due to the strong
involvement of our teams and I would like to thank all our employees
that took part on this important challenge. Considering the strong
experience of Quest Diagnostics in developing CLIA compliant tests, I'm
very confident in their ability to continue the development work that
will bring to physicians and patients a clinically important alternative
to current genetic technologies," concludes Aaron
Bensimon, Genomic Vision's co-founder and Chairman.
Next financial press release
-
2014 annual revenue, on January 15, 2015 (after market)
[ Back To TMCnet.com's Homepage ]
|